Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
Executive Summary
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
You may also be interested in...
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Sanofi Should Take Note: Insiders Might Just Make Better CEOs
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.